Abstract
Urothelial carcinoma is the common malignancy involving the urinary system. Cisplatin-based chemotherapy is the initial regimen of choice for cisplatin-eligible patients with metastatic urothelial carcinoma. However, due to toxicity, the regimen is not well tolerated in part of the patients, such as in elderly patients or those with multiple complications, and there is still a risk of recurrence. During the past years, immune checkpoint inhibitors (ICI) have become available as a new option for urothelial carcinoma patients, with the benefits of clinical efficacy and quality of life. Development and researches of the ICI axis blockade have changed the contemporary treatment paradigm for patients with locally advanced or metastatic urothelial carcinoma. In addition, multiple clinical studies of combined treatment strategies of ICI have been explored recently. It is necessary to further understand the clinical value of ICI through summarizing the evidence supporting the use of checkpoint inhibitors for patients with inoperable locally advanced or metastatic urothelial carcinoma, which also may helpful to perspective the future research direction of combined strategies and precision medicine in urothelial carcinoma immunotherapy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhonghua wai ke za zhi [Chinese journal of surgery]
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
